20 out of 26 panelists vote to either ease restrictions or eliminate them entirely on...


20 out of 26 panelists vote to either ease restrictions or eliminate them entirely on GlaxoSmithKline's (GSK) diabetes treatment Avandia after a two-day meeting at which FDA officials considered the results of a Duke University study which reportedly supports GSK's contention that heart worries surrounding the drug may be overblown.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs